Boston Scientific Corporation to Pay $30 Million Over Defective Heart Devices: DOJ

Published: Oct 18, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Boston Scientific Corp agreed to pay $30 million to settle allegations that the Guidant unit it acquired in 2006 knowingly sold defective heart devices implanted in Medicare patients, the U.S. Justice Department said on Thursday.

Help employers find you! Check out all the jobs and post your resume.

Back to news